518 First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors

• Lixia Wang,
• John Powderly,
• Tanios Bekaii-Saab,
• Susanna Ulahannan,
• Ngan Nguyen,
• Deborah Doroshow,
• Yan Xing,
• Mark Whidden,
• Carl Millward,
• Jonathan Benjamin,
• S John Weroha,
• Frances Valdes-Albini,
• Kimberly Walter,
• Andrew Wrong,
• Paul Del Castillo,
• Steven Isakoff

Affiliations

Lixia Wang

1 National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

John Powderly

1Carolina BioOncology Institute, Huntersville, NC, USA

Tanios Bekaii-Saab

Aff1 grid.261331.40000000122857943The Ohio State University Columbus OH USA

Susanna Ulahannan

4University of Oklahoma Health Sciences C, OKC, OK, USA

Ngan Nguyen

Atreca, Inc, South San Francisco, CA, USA

Deborah Doroshow

1Icahn School of Medicine at Mount Sinai, New York, NY, USA

Yan Xing

4City of Hope, Duarte, CA, USA

Mark Whidden

Atreca, Inc, South San Francisco, CA, USA

Carl Millward

Atreca Inc., South San Francisco, CA, USA

Jonathan Benjamin

Atreca Inc., South San Francisco, CA, USA

S John Weroha

2Mayo Clinic, Jacksonville, FL, USA

Frances Valdes-Albini

6University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

Kimberly Walter

7Atreca, Inc, San Carlos, CA, USA

Andrew Wrong

7Atreca, Inc, San Carlos, CA, USA

Paul Del Castillo

7Atreca, Inc, San Carlos, CA, USA

Steven Isakoff

8Massachusetts General Hospital, Boston, MA, USA